European Patent Office

T 0170/22 (Antidiabetic combinations/JANSSEN) of 03.05.2024

European Case Law Identifier
ECLI:EP:BA:2024:T017022.20240503
Date of decision
3 May 2024
Case number
T 0170/22
Petition for review of
-
Application number
10735109.0
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
COMBINATION THERAPY FOR THE TREATMENT OF DIABETES
Applicant name
Janssen Pharmaceutica NV
Opponent name
Teva Pharmaceutical Industries Ltd.
Generics [UK] Limited
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 56European Patent Convention Art 84European Patent Convention R 80Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(5)Rules of procedure of the Boards of Appeal 2020 Art 012(6)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
Keywords
Main request, auxiliary request 24 - inventive step - reasonable expectation of success (no)
Main request - clarity after amendment (no)
Auxiliary request 1 - amendment to case - admitted (no)
Auxiliary requests 2 to 4 - amendment after notification of A.15(1) RPBA communication - exceptional circumstances (no)
Auxiliary request 24 - substantiation of clarity objection (no)
Auxiliary request 24 - amendments occasioned by ground for opposition (yes), added subject-matter (no), extension of the scope of protection (no)
Catchword
-
Citing cases
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division with the order to maintain the patent on the basis of claims 1 and 2 of auxiliary request 24 filed with the statement of grounds of appeal and a description to be adapted, as needed.